Rho GTPases: Promising cellular targets for novel anticancer drugs

Current Cancer Drug Targets

Volumn 6, Issue 1, 2006, Pages 1-14

  Fritz, Gerhard ^a   Kaina, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cancer drugs; Drug resistance; Genotoxic stress; Metastasis; Rho GTPases; Therapeutic targets; Tumor progression

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; ALKYLATING AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CISPLATIN; DOXORUBICIN; FASUDIL; GUANOSINE TRIPHOSPHATE DERIVATIVE; H 1152 P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENE TRANSFERASE INHIBITOR; MAFOSFAMIDE; MERCAPTOPURINE; MEVINOLIN; NSC 23766; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE THREONINE KINASE INHIBITOR; TREOSULFAN; UNCLASSIFIED DRUG; WF 536; ENZYME INHIBITOR; MUTAGENIC AGENT;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER GROWTH; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL DEATH; CELL FUNCTION; CELL MOTILITY; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DNA DAMAGE; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; HUMAN; IN VIVO STUDY; IONIZING RADIATION; ISOPRENYLATION; MALIGNANT TRANSFORMATION; METASTASIS INHIBITION; ONCOGENE; PLEIOTROPY; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BINDING; REVIEW; TUMOR GROWTH; ANIMAL; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MUTAGENS; RHO GTP-BINDING PROTEINS;

EID: 33644854484     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906775471752     Document Type: Review

References (180)

1. Wennerberg, K.; Rossman, K. L.; Der, C. J. The Ras superfamily at a glance. J. Cell Sci. 2005, 118, 843-846.
2. Bourne, H. R.; Sanders, D. A.; McCormick, F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991, 349, 117-27.
3. Kjoller, L.; Hall, A. Signaling to Rho GTPases. Exp. Cell Res. 1999, 253, 166-79.
4. Van Aelst, L.; D'Souza-Schorey, C. Rho GTPases and signaling networks. Genes Dev. 1997, 11, 2295-322.
5. Cherfils, J.; Chardin, P. GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem. Sci. 1999, 24, 306-311.
6. Erickson, J. W.; Cerione, R. A. Structural elements, mechanism, and evolutionary convergence of Rho protein-guanine nucleotide exchange factor complexes. Biochemistry 2004, 43, 837-842.
7. Rameh, L. E.; Arvidsson, A.; Carraway, K. L. 3rd. Couvillon, A. D.; Rathbun, G.; Crompton, A.; VanRenterghem, B.; Czech, M. P.; Ravichandran, K. S.; Burakoff, S. J.; Wang, D. S.; Chen, C. S.; Cantley, L. C. A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. J. Biol. Chem. 1997, 272, 22059-22066.
8. Bernards, A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim. Biophys. Acta 2003, 1603, 47-82.
9. Rittinger, K.; Walker, P. A.; Eccleston, J. F.; Smerdon, S. J.; Gamblin, S. J. Structure at 1.65 A of RhoA and its GTPase-activating protein in complex with a transition-state analogue. Nature 1997, 389, 758-762.
10. Rittinger, K.; Walker, P. A.; Eccleston, J. F.; Nurmahomed, K.; Owen, D.; Laue, E.; Gamblin, S. J.; Smerdon, S. J. Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP. Nature 1997, 388, 693-697.
11. Adamson, P.; Marshall, C. J.; Hall, A.; Tilbrook, P. A. Posttranslational modifications of p21rho proteins. J. Biol. Chem. 1992, 267, 20033-20038.
12. Zhang, F. L.; Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 1996, 65, 241-69.
13. Cox, A. D.; Der, C. J. Protein prenylation: more than just glue? Curr. Opin. Cell Biol. 1992, 4, 1008-1016.
14. Gosser, Y. Q.; Nomanbhoy, T. K.; Aghazadeh, B.; Manor, D.; Combs, C.; Cerione, R. A.; Rosen, M. K. C-terminal binding domain of Rho GDP-dissociation inhibitor directs N-terminal inhibitory peptide to GTPases. Nature 1997, 387, 814-819.
15. Hoffman, G. R.; Nassar, N.; Cerione, R. A. Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 2000, 100, 345-356.
16. Olofsson, B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal. 1999, 11, 545-554.
17. Seabra, M. C.; Wasmeier, C. Controlling the location and activation of Rab GTPases. Curr. Opin. Cell. Biol. 2004, 16, 451-457.
18. Jaffe, A. B.; Hall, A. Rho GTPases in transformation and metastasis. Adv. Cancer Res. 2002, 84, 57-80.
19. Ellerbroek, S. M.; Wennerberg, K.; Burridge, K. Serine phosphorylation negatively regulates RhoA in vivo. J. Biol. Chem. 2003, 278, 19023-19031.
20. Forget, M. A.; Desrosiers, R. R.; Gingras, D.; Beliveau, R. Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. Biochem. J. 2002, 361, 243-254.
21. Aktories, K.; Wilde, C.; Vogelsgesang, M. Rho-modifying C3-like ADP-ribosyltransferases. Rev. Physiol. Biochem. Pharmacol. 2004, 152, 1-22.
22. Aktories, K.; Schmidt, G.; Just, I. Rho GTPases as targets of bacterial protein toxins. Biol. Chem. 2000, 381, 421-426.
23. Just, I.; Gerhard, R. Large clostridial cytotoxins. Rev. Physiol. Biochem. Pharmacol. 2004, 152, 23-47.
24. Sekine, A.; Fujiwara, M.; Narumiya, S. Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. J. Biol. Chem. 1989, 264, 8602-8605.
25. Genth, H.; Gerhard, R.; Maeda, A.; Amano, M.; Kaibuchi, K.; Aktories, K.; Just, I. Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex. J. Biol. Chem. 2003, 278, 28523-28527.
26. Just, I.; Selzer, J.; Wilm, M.; von Eichel Streiber, C.; Mann, M.; Aktories, K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995, 375, 500-503.
27. Sehr, P.; Joseph, G.; Genth, H.; Just, I.; Pick, E.; Aktories, K. Glucosylation and ADP ribosylation of rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling. Biochemistry 1998, 37, 5296-5304.
28. Schmidt, G.; Aktories, K. Bacterial cytotoxins target Rho GTPases. Naturwissenschaften 1998, 85, 253-261.
29. Hoffmann, C.; Pop, M.; Leemhuis, J.; Schirmer, J.; Aktories, K.; Schmidt, G. The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA. J. Biol. Chem. 2004, 279, 16026-16032.
30. Feig, L. A. Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases. Nat. Cell Biol. 1999, 1, E25-E27.
31. Hall, A. Rho GTPases and the actin cytoskeleton. Science 1998, 279, 509-514.
32. Ridley, A. J.; Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70, 389-399.
33. Ridley, A. J.; Paterson, H. F.; Johnston, C. L.; Diekmann, D.; Hall, A. The small GTP-binding protein rac regulates growth factor induced membrane ruffling. Cell 1992, 70, 401-410.
34. Kozma, R.; Ahmed, S.; Best, A.; Lim, L. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol. Cell. Biol. 1995, 15, 1942-1952.
35. Prokopenko, S. N.; Saint, R.; Bellen, H. J. Untying the Gordian knot of cytokinesis. Role of small G proteins and their regulators. J. Cell Biol. 2000, 148, 843-848.
36. Cox, D.; Chang, P.; Zhang, Q.; Reddy, P. G.; Bokoch, G. M.; Greenberg, S. Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes. J. Exp. Med. 1997, 186, 1487-1494.
37. Caron, E.; Hall, A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 1998, 282, 1717-1721.
38. Nobes, C. D.; Hall, A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol. 1999, 144, 1235-1244.
39. Minden, A.; Lin, A.; Claret, F. -X.; Abo, A.; Karin, M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995, 81, 1147-1157.
40. Coso, A. A.; Chiariello, M.; Yu, J. -C.; Teramoto, H.; Crespo, P.; Xu, N.; Miki, T.; Gutkind, J. S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995, 81, 1137-1146.
41. Zhang, S.; Han, J.; Sells, M. A.; Chernoff, J.; Knaus, U. G.; Ulevitch, R. J.; Bokoch, G. M. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J. Biol. Chem. 1995, 270, 23934-23936.
42. Hill, C. S.; Wynne, J.; Treisman, R. The Rho family GTPases RhoA, Rac1 and CDC42Hs regulate transcriptional activation by SRF. Cell 1995, 81, 1159-1170.
43. Chang, J. H.; Pratt, J. C.; Sawasdikosol, S.; Kapeller, R.; Burakoff, S. J. The small GTP-binding protein Rho potentiates AP-1 transcription in T cells. Mol. Cell. Biol. 1998, 18, 4986-4993.
44. Montaner, S.; Perona, R.; Saniger, L.; Lacal, J. C. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J. Biol. Chem. 1998, 273, 12779-12785.
45. Perona, R.; Montaner, S.; Saniger, L.; Sanchez-Perez, I.; Bravo, R.; Lacal, J. C. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997, 11, 463-475.
46. Debidda, M.; Wang, L.; Zang, H.; Poli, V.; Zheng, Y. A Role of STAT3 in Rho GTPase-regulated Cell Migration and Proliferation. J. Biol. Chem. 2005, 280, 17275-17285.
47. Benitah, S. A.; Valeron, P. F.; Rui, H.; Lacal, J. C. STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol. Biol. Cell 2003, 14, 40-53.
48. Braga, V. M. Small GTPases and regulation of cadherin dependent cell-cell adhesion. Mol. Pathol. 1999, 52, 197-202.
49. Wojciak Stothard, B.; Williams, L.; Ridley, A. J. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J. Cell Biol. 1999, 145, 1293-1307.
50. Nubel, T.; Dippold, W.; Kleinert, H.; Kaina, B.; Fritz, G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J. 2004, 18, 140-142.
51. Clark, E. A.; King, W. G.; Brugge, J. S.; Symons, M.; Hynes, R. O. Integrin-mediated signals regulated by members of the rho family of GTPases. J. Cell Biol. 1998, 142, 573-586.
52. Olson, M. F.; Ashworth, A.; Hall, A. An essential role for Rho, Rac and Cdc42 GTPases in cell cycle progression through G1. Science 1995, 269, 1270-1272.
53. Qiu, R. -G.; Chen, J.; Kirn, D.; McCormick, F.; Symons, M. An essential role for Rac in Ras transformation. Nature 1995, 374, 457-459.
54. Khosravi-Far, R.; Solski, P. A.; Clark, G. F.; Kinch, M. S.; Der, C. J. Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol. 1995, 15, 6443-6453.
55. Abo, A.; Pick, E.; Hall, A.; Totty, N.; Teahan, C. G.; Segal, A. W. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991, 353, 668-670.
56. Laufs, U.; Liao, J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 1998, 273, 24266-24271.
57. Meacci, E.; Vasta, V.; Moorman, J. P.; Bobak, D. A.; Bruni, P.; Moss, J.; Vaughan, M. Effect of Rho and ADP-ribosylation factor GTPases on phospholipase D activity in intact human adenocarcinoma A549 cells. J. Biol. Chem. 1999, 274, 18605-18612.
58. Esteve, P.; Del-Peso, L.; Lacal, J. C. Induction of apoptosis by rho in NIH3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis. Oncogene 1995, 11, 2657-2665.
59. Esteve, P.; Embade, N.; Perona, R.; Jimenez, B.; del Peso, L.; Leon, J.; Arends, M.; Miki, T.; Lacal, J. C. Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway. Oncogene 1998, 17, 1855-1869.
60. Fritz, G.; Kaina, B. Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem. Biophys. Res. Commun. 2000, 268, 784-789.
61. Liu, A. -X.; Cerniglia, G. J.; Bernhard, E. J.; Prendergast, G. C. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc. Natl. Acad. Sci. USA 2001, 98, 6192-6197.
62. Bishop, A. L.; Hall, A. Rho GTPases and their effector proteins. Biochem. J. 2000, 348, 241-255.
63. Westwick, J. K.; Lambert, Q. T.; Clark, G. J.; Symons, M.; Van Aelst, L.; Pestell, R. G.; Der Channing, J. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol. Cell. Biol. 1997, 17, 1324-1335.
64. Fujisawa, K.; Madaule, P.; Ishizaki, T.; Watanabe, G.; Bito, H.; Saito, Y.; Hall, A.; Narumiya, S. Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules. J. Biol. Chem. 1998, 273, 18943-18949.
65. Lamarche, N.; Tapon, N.; Stowers, L.; Burbelo, P. D.; Aspenstrom, P.; Bridges, T.; Chant, J.; Hall, A. Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade. Cell 1996, 87, 519-529.
66. Diekmann, D.; Nobes, C. D.; Burbelo, P. D.; Abo, A.; Hall, A. Rac GTPase interacts with GAPs and target proteins through multiple effector sites. EMBO J. 1995, 14, 5297-5305.
67. Birchmeier, W.; Birchmeier, C. Epithelial-mesenchymal transitions in development and tumor progression. EXS 1995, 74, 1-15.
68. Schmitz, A. A. P.; Govek, E. E.; Böttner, B.; Van Aelst, L. Rho GTPases: signaling, migration and invasion. Exp. Cell Res. 2000, 261, 1-12.
69. Tokman, M. G.; Porter, R. A.; Williams, C. L. Regulation of cadherin-mediated adhesion by the small GTP-binding protein Rho in small cell lung carcinoma cells. Cancer Res. 1997, 57, 1785-93.
70. Braga, V. M.; Del Maschio, A.; Machesky, L.; Dejana, E. Regulation of cadherin function by Rho and Rac: modulation by junction maturation and cellular context. Mol. Biol. Cell. 1999, 10, 9-22.
71. Krause, T.; Turner, G. A. Are selectins involved in metastasis? Clin. Exp. Metastasis 1999, 17, 183-192.
72. Zhuge, Y.; Xu, J. Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell invasion across collagen barrier. J. Biol. Chem. 2001, 276, 16248-16256.
73. Ikoma, T.; Takahashi, T.; Nagano, S.; Li, Y. M.; Ohno, Y.; Ando, K.; Fujiwara, T.; Fujiwara, H.; Kosai, K. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin. Cancer Res. 2004, 10, 1192-1200.
74. Knight-Krajewski, S.; Welsh, C. F.; Liu, Y.; Lyons, L. S.; Faysal, J. M.; Yang, E. S.; Burnstein, K. L. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 2004, 23, 5513-5522.
75. Welsh, C. F. Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation. Breast Cancer Res. Treat. 2004, 84, 33-42.
76. Coleman, M. L.; Marshall, C. J.; Olson, M. F. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol. 2004, 5, 355-366.
77. Perona, R.; Esteve, P.; Jimenez, B.; Ballestero, R. P.; Ramon y Cajal, S.; Lacal, J. C. Tumorigenic activity of rho genes from Aplysia californica. Oncogene 1993, 8, 1285-1292.
78. Prendergast, G. C.; Khosravi-Far, R.; Solski, P. A.; Kurzawa, H.; Lebowitz, P. F.; Der, C. J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995, 10, 2289-2296.
79. Khosravi-Far, R.; Solski, P. A.; Clark, G. J.; Kinch, M. S.; Der, C. J. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell Biol .1995, 15, 6443-6453.
80. Canman, C. E.; Kastan, M. B. Three paths to stress relief. Nature 1996, 384, 213-214.
81. Soga, N.; Namba, N.; McAllister, S.; Cornelius, L.; Teitelbaum, S. L.; Dowdy, S. F.; Kawamura, J.; Hruska, K. A. Rho family GTPases regulate VEGF-stimulated endothelial cell motility. Exp. Cell Res. 2001, 269, 73-87.
82. van Golen, K. L.; Bao, L. W.; Pan, Q.; Miller, F. R.; Wu, Z. F.; Merajver, S. D. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin. Exp. Metastasis 2002, 19, 301-311.
83. Overbeck, A. F.; Brtva, T. R.; Cox, A. D.; Graham, S. M.; Huff, S. Y.; Khosravi-Far, R.; Quilliam, L. A.; Solski, P. A.; Der, C. J. Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Mol. Reprod. Dev. 1995, 42, 468-476.
84. Clark, E. A.; Golub, T. R.; Lander, E. S.; Hynes, R. O. Genomic analysis of metastasis reveals an essential role for RhoC [see comments]. Nature 2000, 406, 532-535.
85. Yoshioka, K.; Matsumura, F.; Akedo, H.; Itoh, K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J. Biol. Chem. 1998, 273, 5146-5154.
86. Stam, J. C.; Michiels, F.; van der Kammen, R. A.; Moolenaar, W. H.; Collard, J. G. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J. 1998, 17, 4066-4074.
87. Adnane, J.; Muro-Cacho, C.; Mathews, L.; Sebti, S. M.; Munoz-Antonia, T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin. Cancer Res. 2002, 8, 2225-2232.
88. Itoh, K.; Yoshioka, K.; Akedo, H.; Uehata, M.; Ishizaki, T.; Narumiya, S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999, 5, 221-225.
89. Chen, Z.; Sun, J.; Pradines, A.; Favre, G.; Adnane, J.; Sebti, S. M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 2000, 275, 17974-17978.
90. Jiang, K.; Sun, J.; Cheng, J.; Djeu, J. Y.; Wei, S.; Sebti, S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol. Cell. Biol. 2004, 24, 5565-5576.
91. Jiang, K.; Delarue, F. L.; Sebti, S. M. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 2004, 23, 1136-1145.
92. Abraham, M. T.; Kuriakose, M. A.; Sacks, P. G.; Yee, H.; Chiriboga, L.; Bearer, E. L.; Delacure, M. D. Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope 2001, 111, 1285-1289.
93. Suwa, H.; Ohshio, G.; Imamura, T.; Watanabe, G.; Arii, S.; Imamura, M.; Narumiya, S.; Hiai, H.; Fukumoto, M. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer 1998, 77, 147-152.
94. Pan, Y.; Bi, F.; Liu, N.; Xue, Y.; Yao, X.; Zheng, Y.; Fan, D. Expression of seven main Rho family members in gastric carcinoma. Biochem. Biophys. Res. Commun. 2004, 315, 686-691.
95. Kamai, T.; Yamanishi, T.; Shirataki, H.; Takagi, K.; Asami, H.; Ito, Y.; Yoshida, K. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin. Cancer Res. 2004, 10, 4799-4805.
96. Fritz, G.; Brachetti, T.; Bahlmann, F.; Schmidt, M.; Kaina, B. Rho GTPases in human breast tumors: expression and mutation analysis and correlation with clinical parameters. Brit. J. Cancer 2002, 87, 635-644.
97. Jiang, W. G.; Watkins, G.; Lane, J.; Cunnick, G. H.; Douglas-Jones, A.; Mokbel, K.; Mansel, R. E. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin. Cancer Res. 2003, 9, 6432-6440.
98. Burbelo, P.; Wellstein, A.; Pestell, R. G. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res. Treat. 2004, 84, 43-48.
99. Lin, M.; van Golen, K. L. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res. Treat. 2004, 84, 49-60.
100. Jordan, P.; Brazao, R.; Boavida, M. G.; Gespach, C.; Chastre, E. Clon ing of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 1999, 8, 6835-6839.
101. Schnelzer, A.; Prechtel, D.; Knaus, U.; Dehne, K.; Gerhard, M.; Graeff, H.; Harbeck, N.; Schmitt, M.; Lengyel, E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000, 19, 3013-3020.
102. Forget, M. A.; Desrosiers, R. R.; Del, M.; Moumdjian, R.; Shedid, D.; Berthelet, F.; Beliveau, R. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin. Exp. Metastasis 2002, 19, 9-15.
103. Preudhomme, C.; Roumier, C.; Hildebrand, M. P.; Dallery-Prudhomme, E.; Lantoine, D.; Lai, J. L.; Daudignon, A.; Adenis, C.; Bauters, F.; Fenaux, P.; Kerckaert, J. P.; Galiegue-Zouitina, S. Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene 2000, 19, 2023-2032.
104. Benitah, S. A.; Valeron, P. F.; van Aelst, L.; Marshall, C. J.; Lacal, J. C. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim. Biophys. Acta 2004, 1705, 121-132.
105. Ridley, A. J. Rho proteins and cancer. Breast Cancer Res. Treat. 2004, 84, 13-19.
106. Aznar, S.; Fernandez-Valeron, P.; Espina, C.; Lacal, J. C. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 2004, 206, 181-191.
107. Campbell, P. M.; Der, C. J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 2004, 14, 105-114.
108. Oxford, G.; Theodorescu, D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett. 2003, 189, 117-128.
109. Cox, A. D.; Der, C. J. Ras family signaling: therapeutic targeting. Cancer Biol. Ther. 2002, 1, 599-606.
110. Sebti, S. M. Blocked pathways: FTIs shut down oncogene signals. Oncologist 2003, 8(Suppl 3), 30-38.
111. Durocher, D.; Jackson, S. P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opini. Cell Biol. 2001, 13, 225-231.
112. Cortez, D.; Guntuku, S.; Qin, J.; Elledge, S. J. ATR and ATRIP: partners in checkpoint signaling. Science 2001, 294, 1713-1716.
113. Ichijo, H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18, 6087-6093.
114. Ichijo, H.; Nishida, E.; Irie, K.; ten-Dijke, P.; Saitoh, M.; Moriguchi, T.; Takagi, M.; Matsumoto, K.; Miyazono, K.; Gotoh, Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275, 90-94.
115. Li, W.; Chong, H.; Guan, K. L. Function of the Rho family GTPases in Ras-stimulated Raf activation. J. Biol. Chem. 2001, 276, 34728-34737.
116. Arai, A.; Kanda, E.; Miura, O. Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway. Oncogene 2002, 21, 2641-2651.
117. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R. J.; Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270, 1326-1331.
118. Verheij, M.; Bose, R.; Lin, X. H.; Yao, B.; Jarvis, W. D.; Grant, S.; Birrer, M. J.; Szabo, E.; Zon, L. I.; Kyriakis, J. M.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R. N. Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis. Nature 1996, 380, 75-79.
119. Sanchez Perez, I.; Murguia, J. R.; Perona, R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998, 16, 533-540.
120. Brozovic, A.; Fritz, G.; Christmann, M.; Zisowsky, J.; Jaehde, U.; Osmak, M.; Kaina, B. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int. J. Cancer 2004, 112, 974-985.
121. Potapova, O.; Haghighi, A.; Bost, F.; Liu, C.; Birrer, M. J.; Gjerset, R.; Mercola, D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 1997, 272, 14041-14044.
122. Hayakawa, J.; Mittal, S.; Wang, Y.; Korkmaz, K. S.; Adamson, E.; English, C.; Ohmichi, M.; McClelland, M.; Mercola, D. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol. Cell 2004, 16, 521-535.
123. Gnad, R.; Kaina, B.; Fritz, G. Rho GTPases are involved in the regulation of NF-kB by genotoxic stress. Exp. Cell Res. 2001, 264, 244-249.
124. Wang, C. Y.; Mayo, M. W.; Baldwin, A. S., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274, 784-787.
125. Fritz, G.; Kaina, B.; Aktories, K. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J. Biol. Chem. 1995, 270, 25172-25177.
126. Fritz, G.; Kaina, B. rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase. J. Biol. Chem. 1997, 272, 30637-306344.
127. Jähner, D.; Hunter, T. The ras-related gene rhoB is an immediate early gene inducible by v-Fps, epidermal growth factor and platelet-derived growth factor in rat fibroblasts. Mol. Cell. Biol. 1991, 11, 3682-3690.
128. Fritz, G.; Kaina, B. Transcriptional activation of the small GTPase gene rhoB by genotoxic stress is regulated via a CCAAT element. Nucleic Acids Res. 2001, 29, 792-798.
129. Fritz, G.; Kaina, B. Ras-related GTPase RhoB represses NF-kappaB signaling. J. Biol. Chem. 2001, 276, 3115-3122.
130. Bardeleben, R.; Kaina, B.; Fritz, G. Ultraviolet light-induced apoptotic death is impaired by the HMG-CoA reductase inhibitor lovastatin. Biochem. Biophys. Res. Commun. 2003, 307, 401-407.
131. Miller, A. C.; Samid, D. Tumor resistance to oxidative stress:association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer 1995, 60, 249-254.
132. Feleszko, W.; Mlynarczuk, I.; Balkowiec-Iskra, E. Z.; Czajka, A.; Switaj, T.; Stoklosa, T.; Giermasz, A.; Jakobisiak, M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. 2000, 6, 2044-2052.
133. Schmidmaier, R.; Baumann, P.; Simsek, M.; Dayyani, F.; Emmerich, B.; Meinhardt, G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104, 1825-1832.
134. Kozar, K.; Kaminski, R.; Legat, M.; Kopec, M.; Nowis, D.; Skierski, J. S.; Koronkiewicz, M.; Jakobisiak, M.; Golab, J. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol. 2004, 24, 1149-1157.
135. Lebowitz, P. F.; Prendergast, G. C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998, 17, 1439-1445.
136. Bernhard, E. J.; McKenna, W. G.; Hamilton, A. D.; Sebti, S. M.; Qian, Y.; Wu, J. M.; Muschel, R. J. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 1998, 58, 1754-1761.
137. Smalley, K. S.; Eisen, T. G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer 2003, 105, 165-175.
138. Miller, A. C.; Kariko, K.; Myers, C. E.; Clark, E. P.; Samid, D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer 1993, 53, 302-307.
139. von Bardeleben, R.; Dunkern, T.; Kaina, B.; Fritz, G. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int. J. Mol. Med. 2002, 10, 473-479.
140. Fritz, G.; Brachetti, C.; Kaina, B. Lovastatin causes sensitization of HeLa cells to ionizing radiation-induced apoptosis by the abrogation of G2 blockage. Int. J. Radiat. Biol. 2003, 79, 601-610.
141. Schafer, W. R.; Rine, J. Protein prenylation: genes, enzymes, targets, and functions. Ann. Rev. Genet. 1992, 26, 209-237.
142. Farnier, M.; Davignon, J. Current and future treatment of hyperlipidemia: the role of statins. Am. J. Cardiol. 1998, 82, 3j-10j.
143. Mehta, J. L. Pleiotropic effects of statins: how important are they in the prevention of vascular disease? Endothelium 2003, 10, 3-4.
144. Denoyelle, C.; Vasse, M.; Korner, M.; Mishal, Z.; Ganne, F.; Vannier, J. P.; Soria, J.; Soria, C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001, 22, 1139-1148.
145. Chan, K. K.; Oza, A. M.; Siu, L. L. The statins as anticancer agents. Clin. Cancer Res. 2003, 9, 10-19.
146. Nubel, T.; Dippold, W.; Kaina, B.; Fritz, G. Ionizing radiation-induced E-selectin gene expression and tumor cell adhesion is inhibited by lovastatin and all-trans retinoic acid. Carcinogenesis 2004, 25, 1335-1344.
147. Shibata, M. A.; Ito, Y.; Morimoto, J.; Otsuki, Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004, 25, 1887-1898.
148. Mackay, H. J.; Hoekstra, R.; Eskens, F. A.; Loos, W. J.; Crawford, D.; Voi, M.; Van Vreckem, A.; Evans, T. R.; Verweij, J. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clin. Cancer Res. 2004, 10, 2636-2644.
149. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Exp. Opin. Investig. Drugs 2000, 9, 2767-2782.
150. Adjei, A. A.; Croghan, G. A.; Erlichman, C.; Marks, R. S.; Reid, J. M.; Sloan, J. A.; Pitot, H. C.; Alberts, S. R.; Goldberg, R. M.; Hanson, L. J.; Bruzek, L. M.; Atherton, P.; Thibault, A.; Palmer, P. A.; Kaufmann, S. H. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 2003, 9, 2520-2526.
151. Gibbs, J. B.; Kohl, N. E.; Koblan, K. S.; Omer, C. A.; Sepp-Lorenzino, L.; Rosen, N.; Anthony, N. Y.; Conner, M. W.; deSolms, S. J.; Williams, T. M.; Graham, S. L.; Hartman, G. D.; Oliff, A. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res. Treat. 1996, 38, 75-83.
152. Du, W.; Lebowitz, P. F.; Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 1999, 19, 1831-1840.
153. Mertens, A. E.; Roovers, R. C.; Collard, J. G. Regulation of Tiam1-Rac signalling. FEBS Lett. 2003, 546, 11-16.
154. Yaku, H.; Sasaki, T.; Takai, Y. The Dbl oncogene product as a GDP/GTP exchange protein for the Rho family: its properties in comparison with those of Smg GDS. Biochem. Biophys. Res. Commun. 1994, 198, 811-817.
155. Movilla, N.; Dosil, M.; Zheng, Y.; Bustelo, X. R. How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42. Oncogene 2001, 20, 8057-8065.
156. van Leeuwen, F. N.; van der Kammen, R. A.; Habets, G. G.; Collard, J. G. Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene 1995, 11, 2215-2221.
157. Hordijk, P. L.; ten Klooster, J. P.; van der Kammen, R. A.; Michiels, F.; Oomen, L. C.; Collard, J. G. Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. Science 1997, 278, 1464-1466.
158. Collard, J. G.; Habets, G. G.; Michiels, F.; Stam, J.; van der Kammen, R. A.; van Leeuwen, F. Role of Tiam 1 in Rac-mediated signal transduction pathways. Curr. Top. Microbiol. Immunol. 1996, 213( Pt 2), 253-265.
159. Gerhard, R.; Tatge, H.; Genth, H.; Thum, T.; Borlak, J.; Fritz, G.; Just, I. Clostridium difficile Toxin A Induces Expression of the Stress-induced Early Gene Product RhoB. J. Biol. Chem. 2005, 280, 1499-1505.
160. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H. A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P. R.; Ahmadian, M. R.; Neurath, M. F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 2003, 111, 1133-1145.
161. Gao, Y.; Dickerson, J. B.; Guo, F.; Zheng, J.; Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. USA 2004, 101, 7618-7623.
162. Narumiya, S.; Ishizaki, T.; Uehata, M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol. 2000, 325, 273-284.
163. Ishizaki, T.; Uehata, M.; Tamechika, I.; Keel, J.; Nonomura, K.; Maekawa, M.; Narumiya, S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 2000, 57, 976-983.
164. Matsui, T.; Amano, M.; Yamamoto, T.; Chihara, K.; Nakafuku, M.; Ito, M.; Nakano, T.; Okawa, K.; Iwamatsu, A.; Kaibuchi, K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996, 15, 2208-2216.
165. Amano, M.; Ito, M.; Kimura, K.; Fukata, Y.; Chihara, K.; Nakano, T.; Matsuura, Y.; Kaibuchi, K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 1996, 271, 20246-20249.
166. Fukata, Y.; Amano, M.; Kaibuchi, K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 2001, 22, 32-39.
167. Segain, J. P.; Raingeard de la Bletiere, D.; Sauzeau, V.; Bourreille, A.; Hilaret, G.; Cario-Toumaniantz, C.; Pacaud, P.; Galmiche, J. P.; Loirand, G. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 2003, 124, 1180-1187.
168. Nakajima, M.; Hayashi, K.; Katayama, K.; Amano, Y.; Egi, Y.; Uehata, M.; Goto, N.; Kondo, T. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur. J. Pharmacol. 2003, 459, 113-120.
169. Nakajima, M.; Hayashi, K.; Egi, Y.; Katayama, K.; Amano, Y.; Uehata, M.; Ohtsuki, M.; Fujii, A.; Oshita, K.; Kataoka, H.; Chiba, K.; Goto, N.; Kondo, T.
170. Somlyo, A. V.; Phelps, C.; Dipierro, C.; Eto, M.; Read, P.; Barrett, M.; Gibson, J. J.; Burnitz, M. C.; Myers, C.; Somlyo, A. P. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J. 2003, 17, 223-234.
171. Hirooka, Y.; Shimokawa, H. Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases. Am. J. Cardiovasc. Drugs 2005, 5, 31-39.
172. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
173. Sasaki, Y.; Suzuki, M.; Hidaka, H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 2002, 93, 225-232.
174. Breitenlechner, C.; Gassel, M.; Hidaka, H.; Kinzel, V.; Huber, R.; Engh, R. A.; Bossemeyer, D. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure (Camb.) 2003, 11, 1595-1 607.
175. Blencke, S.; Zech, B.; Engkvist, O.; Greff, Z.; Orfi, L.; Horvath, Z.; Keri, G.; Ullrich, A.; Daub, H. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 2004, 11, 691-701.
176. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303, 1800-1805.
177. Tanno, S.; Ohsaki, Y.; Nakanishi, K.; Toyoshima, E.; Kikuchi, K. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839). Oncol. Rep. 2004, 12, 1053-1057.
178. Xia, W.; Mullin, R. J.; Keith, B. R.; Liu, L. H.; Ma, H.; Rusnak, D. W.; Owens, G.; Alligood, K. J.; Spector, N. L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21, 6255-6263.
179. Druker, B. J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 2004, 91, 1-30.
180. Tseng, P. H.; Lin, H. P.; Zhu, J.; Chen, K. F.; Hade, E. M.; Young, D. C.; Byrd, J. C.; Grever, M.; Johnson, K.; Druker, B. J.; Chen, C. S. Synergistic interactions between imatinib and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib resistance. Blood 2005, 105, 4021-4027.